Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000229061 | SCV000283153 | uncertain significance | Bloom syndrome | 2023-07-31 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 236823). This variant has not been reported in the literature in individuals affected with BLM-related conditions. This variant is present in population databases (rs770111029, gnomAD 0.01%). This sequence change replaces glutamine, which is neutral and polar, with arginine, which is basic and polar, at codon 224 of the BLM protein (p.Gln224Arg). |
Ambry Genetics | RCV002372242 | SCV002667307 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-09-27 | criteria provided, single submitter | clinical testing | The p.Q224R variant (also known as c.671A>G), located in coding exon 2 of the BLM gene, results from an A to G substitution at nucleotide position 671. The glutamine at codon 224 is replaced by arginine, an amino acid with highly similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000229061 | SCV002089962 | uncertain significance | Bloom syndrome | 2021-08-16 | no assertion criteria provided | clinical testing |